JP2007517060A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517060A5 JP2007517060A5 JP2006547565A JP2006547565A JP2007517060A5 JP 2007517060 A5 JP2007517060 A5 JP 2007517060A5 JP 2006547565 A JP2006547565 A JP 2006547565A JP 2006547565 A JP2006547565 A JP 2006547565A JP 2007517060 A5 JP2007517060 A5 JP 2007517060A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- parkinson
- pharmaceutical composition
- central nervous
- nervous system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000018737 Parkinson disease Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000015114 central nervous system disease Diseases 0.000 claims 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 4
- 229960003433 thalidomide Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000014825 Abnormal muscle tone Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010013952 Dysphonia Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 208000022084 motor paralysis Diseases 0.000 claims 1
- 230000001703 neuroimmune Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53386403P | 2003-12-30 | 2003-12-30 | |
| PCT/US2004/043925 WO2005065372A2 (en) | 2003-12-30 | 2004-12-27 | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517060A JP2007517060A (ja) | 2007-06-28 |
| JP2007517060A5 true JP2007517060A5 (https=) | 2007-10-25 |
Family
ID=34748975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547565A Abandoned JP2007517060A (ja) | 2003-12-30 | 2004-12-27 | 中枢神経系障害又は疾患の治療又は管理のためのサリドマイドを用いた方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050182097A1 (https=) |
| EP (1) | EP1704186A4 (https=) |
| JP (1) | JP2007517060A (https=) |
| KR (1) | KR20060128961A (https=) |
| CN (1) | CN1921857A (https=) |
| AU (1) | AU2004311421A1 (https=) |
| BR (1) | BRPI0417913A (https=) |
| CA (1) | CA2551518A1 (https=) |
| IL (1) | IL176453A0 (https=) |
| NZ (1) | NZ548537A (https=) |
| WO (1) | WO2005065372A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| US20060258708A1 (en) * | 2005-05-16 | 2006-11-16 | Andrulis Peter J Jr | Method for treating Parkinson's disease and other neurological diseases |
| US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
| WO2011154739A1 (en) * | 2010-06-09 | 2011-12-15 | Generics [Uk] Limited | Crystalline forms of thalidomide and processes for their preparation |
| US10272117B2 (en) | 2014-02-24 | 2019-04-30 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
| JP6930969B2 (ja) | 2015-07-08 | 2021-09-01 | ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
| US5739119A (en) * | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| FR2756737B1 (fr) * | 1996-12-05 | 1999-01-08 | Rhone Poulenc Rorer Sa | Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens |
| DE19743968C2 (de) * | 1997-10-06 | 2002-07-11 | Gruenenthal Gmbh | Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen |
| US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
| US20030185826A1 (en) * | 1999-02-24 | 2003-10-02 | Tobinick Edward L. | Cytokine antagonists for the treatment of localized disorders |
| US6419934B1 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
| US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
| US6015557A (en) * | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US6537549B2 (en) * | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US20030007972A1 (en) * | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
| US20030113318A1 (en) * | 1999-02-24 | 2003-06-19 | Tobinick Edward Lewis | TNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrhea |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| EP1313460A2 (en) * | 1999-11-09 | 2003-05-28 | Darwin Discovery Limited | Therapeutic use and formulation of (-)-tramadol |
| US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| DE50304744D1 (de) * | 2003-04-28 | 2006-10-05 | Biofrontera Bioscience Gmbh | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis |
-
2004
- 2004-12-23 US US11/022,065 patent/US20050182097A1/en not_active Abandoned
- 2004-12-27 CA CA002551518A patent/CA2551518A1/en not_active Abandoned
- 2004-12-27 KR KR1020067015163A patent/KR20060128961A/ko not_active Withdrawn
- 2004-12-27 AU AU2004311421A patent/AU2004311421A1/en not_active Abandoned
- 2004-12-27 CN CNA2004800422099A patent/CN1921857A/zh active Pending
- 2004-12-27 NZ NZ548537A patent/NZ548537A/en not_active Application Discontinuation
- 2004-12-27 EP EP04815915A patent/EP1704186A4/en not_active Withdrawn
- 2004-12-27 WO PCT/US2004/043925 patent/WO2005065372A2/en not_active Ceased
- 2004-12-27 JP JP2006547565A patent/JP2007517060A/ja not_active Abandoned
- 2004-12-27 BR BRPI0417913-7A patent/BRPI0417913A/pt not_active IP Right Cessation
-
2006
- 2006-06-20 IL IL176453A patent/IL176453A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517059A5 (https=) | ||
| JP2007517060A5 (https=) | ||
| RU2489155C2 (ru) | Лечение нейродегенеративных заболеваний | |
| US20180072671A1 (en) | Inhibitors of histone deacetylase | |
| WO2004087116A3 (es) | Combinación de drogas para la disfunción motora en la enfermedad de parkinson | |
| JP2007523168A5 (https=) | ||
| WO2007118185A3 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
| WO2009067703A3 (en) | Tapentadol compositions | |
| JP2009510064A5 (https=) | ||
| WO2007002013A3 (en) | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | |
| MX2007005306A (es) | Formas de dosis oral de liberacion sostenida de la prodroga gabapentina. | |
| TW200800957A (en) | New compounds | |
| MXPA05009524A (es) | Derivados de imidazol-4-il-etinil-piridina. | |
| CL2008000738A1 (es) | Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| US8138377B2 (en) | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | |
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a | |
| WO2008111590A3 (en) | Ampa and nmda receptor antagonists for neurodegenerative diseases | |
| JP2019533642A5 (https=) | ||
| JPWO2021111124A5 (https=) | ||
| JP2004532828A5 (https=) | ||
| WO2009121155A3 (en) | Flavone containing compositions for treating mao associated disorders | |
| MX2023012521A (es) | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. | |
| JP2007501270A5 (https=) | ||
| JP2007530703A5 (https=) |